TABLE 1.
Clinical characteristics of patients in the primary and validation cohorts
| Primary cohort | p-value | Validation cohort | p-value | |||
| EGFR-wild type | EGFR-mutant | EGFR-wild type | EGFR-mutant | |||
| Subjects n | 603 | 241 | ||||
| Age years | 59.50±9.72 | 61.36±8.96 | 0.016 | 59.59±8.83 | 59.21±7.28 | 0.716 |
| Sex | <0.001 | <0.001 | ||||
| Female | 99 (39.76) | 206 (58.19) | 52 (42.62) | 79 (66.39) | ||
| Male | 150 (60.24) | 148 (41.81) | 70 (57.38) | 40 (33.61) | ||
| Stage | 0.047 | 0.017 | ||||
| I | 181 (72.69) | 240 (67.80) | 50 (40.98) | 65 (54.62) | ||
| II | 27 (10.84) | 27 (7.63) | 22 (18.03) | 8 (6.72) | ||
| III | 36 (14.46) | 69 (19.49) | 43 (35.25) | 35 (29.41) | ||
| IV | 5 (2.01) | 18 (5.08) | 7 (5.74) | 11 (9.24) | ||
| EGFR mutation | 249 (41.29) | 354 (58.71) | 122 (50.62) | 119 (49.38) | ||
Data are presented as mean±sd, or n (%), unless otherwise stated. EGFR: epidermal growth factor receptor.